CVSS2
Attack Vector
LOCAL
Attack Complexity
LOW
Authentication
NONE
Confidentiality Impact
PARTIAL
Integrity Impact
PARTIAL
Availability Impact
PARTIAL
AV:L/AC:L/Au:N/C:P/I:P/A:P
CVSS3
Attack Vector
PHYSICAL
Attack Complexity
LOW
Privileges Required
NONE
User Interaction
NONE
Scope
UNCHANGED
Confidentiality Impact
HIGH
Integrity Impact
HIGH
Availability Impact
HIGH
CVSS:3.1/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
AI Score
Confidence
High
EPSS
Percentile
32.8%
CVSS v3 6.8
ATTENTION: Low skill level to exploit
Vendor: Becton, Dickinson and Company (BD)
**Equipment:**FACSLyric
Vulnerability: Improper Access Control
This updated medical device advisory is a follow-up to the original advisory titled ICSMA-19-029-02 BD FACSLyric that was published January 29, 2019, on the NCCIC/ICS-CERT website.
Successful exploitation of this vulnerability may allow an attacker to gain unauthorized access to administrative level privileges on a workstation, which could allow arbitrary execution of commands. This vulnerability does not impact BD FACSLyric flow cytometry systems using the Windows 7 Operating System.
The following versions of the FACSLyric flow cytometry solution are affected:
--------- Begin Update A Part 1 of 1 ---------
The system does not properly enforce user access control to a privileged account, which may allow for unauthorized access to administrative level functions.
CVE-2019-6517 has been assigned to this vulnerability. A CVSS v3 base score of 6.8 has been calculated; the CVSS vector string is (AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H).
--------- End Update A Part 1of 1 ---------
BD reported this vulnerability to NCCIC.
BD will follow-up directly with all affected users to perform remediation activities. BD will disable the administrative account for users with BD FACSLyric RUO Cell Analyzer units having the Windows 10 Pro Operating System. BD has contacted and will replace the computer workstations for affected users with the BD FACSLyric IVD Cell Analyzer units with the Windows 10 Pro Operating System.
For additional information regarding the reported vulnerability please contact BD for the following support:
For technical support, please contact the BD Biosciences General Tech Support - Flow Cytometry via email [email protected] or phone 877-232-8995 Option 2 and then Option 2 again.
For more information on BD’s product security and vulnerability management, contact BD’s Product Security Office:
<https://www.bd.com/productsecurity>
NCCIC recommends users take defensive measures to minimize the risk of exploitation of this vulnerability. Specifically, users should:
NCCIC reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
NCCIC also provides a section for control systems security recommended practices on the ICS-CERT web page. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Additional mitigation guidance and recommended practices are publicly available on the ICS-CERT website in the Technical Information Paper, ICS-TIP-12-146-01B–Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to NCCIC for tracking and correlation against other incidents.
No known public exploits specifically target this vulnerability. This vulnerability is not exploitable remotely.
web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2019-6517
cisasurvey.gov1.qualtrics.com/jfe/form/SV_9n4TtB8uttUPaM6?product=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-19-029-02
cwe.mitre.org/data/definitions/284.html
public.govdelivery.com/accounts/USDHSCISA/subscriber/new?topic_id=USDHSCISA_138
twitter.com/CISAgov
twitter.com/intent/tweet?text=BD%20FACSLyric%20%28Update%20A%29+https://www.cisa.gov/news-events/ics-medical-advisories/icsma-19-029-02
www.bd.com/productsecurity
www.dhs.gov
www.dhs.gov/foia
www.dhs.gov/performance-financial-reports
www.facebook.com/CISA
www.facebook.com/sharer/sharer.php?u=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-19-029-02&title=BD%20FACSLyric%20%28Update%20A%29
www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
www.instagram.com/cisagov
www.linkedin.com/company/cybersecurity-and-infrastructure-security-agency
www.linkedin.com/sharing/share-offsite/?url=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-19-029-02
www.oig.dhs.gov/
www.usa.gov/
www.whitehouse.gov/
www.youtube.com/@cisagov
mailto:?subject=BD%20FACSLyric%20%28Update%20A%29&body=www.cisa.gov/news-events/ics-medical-advisories/icsma-19-029-02
CVSS2
Attack Vector
LOCAL
Attack Complexity
LOW
Authentication
NONE
Confidentiality Impact
PARTIAL
Integrity Impact
PARTIAL
Availability Impact
PARTIAL
AV:L/AC:L/Au:N/C:P/I:P/A:P
CVSS3
Attack Vector
PHYSICAL
Attack Complexity
LOW
Privileges Required
NONE
User Interaction
NONE
Scope
UNCHANGED
Confidentiality Impact
HIGH
Integrity Impact
HIGH
Availability Impact
HIGH
CVSS:3.1/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
AI Score
Confidence
High
EPSS
Percentile
32.8%